Hawkins Buys Eagle Labs, Adds Two Texas Water Sites

Hawkins, Inc. (Nasdaq: HWKN) said on 29 September 2026 that it has completed the acquisition of the assets of Eagle Labs, Inc., a North Texas water treatment distributor with in-house manufacturing. The deal adds two Dallas–Fort Worth locations, lifting Hawkins' Water Treatment footprint in Texas to seven facilities. Hawkins reported roughly $1.1 billion of revenue in fiscal 2026 and counts about 1,200 employees across 69 facilities in 28 states. The purchase price was not disclosed in the announcement.

Context — why Texas water treatment is the growth story here

Hawkins frames the deal as an extension of a Texas build-out that began in fiscal 2022, the year the company first entered the state. Since then it has assembled seven Water Treatment facilities there, and Eagle Labs supplies the two newest. The company's stated logic is geographic: Texas is now the world's eighth-largest economy, and Dallas–Fort Worth has been the fastest-growing of the top five U.S. metros since 2020, according to CEO Patrick H. Hawkins.

That framing matters because Hawkins' Texas presence is a stated growth pillar rather than a legacy position. The company said the acquisition "extends our reach into the Dallas–Fort Worth region and continues our growth in the State of Texas." Eagle Labs distributes water treatment products directly to customers and manufactures in-house, so Hawkins absorbs both a distribution book and production capacity in one transaction.

Hawkins also disclosed that it has opened a new Hawkins facility in the Dallas–Fort Worth area, separate from the Eagle Labs operations. The two additions together are described as strengthening the company's ability to serve regional demand.

What changed to make this happen now is Eagle Labs' own succession decision. Founder and CEO Dwight Hodel said it was "time to find the one company to trust with our legacy," citing Hawkins' resources and shared values. Hodel's statement is a seller's rationale, not a Hawkins forecast, and the company has not published integration targets or a revenue contribution for the acquired assets.

Data — what the numbers show

The disclosed figures are operating scale, not deal economics. Hawkins operates 69 facilities across 28 states, employs roughly 1,200 people, and generated approximately $1.1 billion of revenue in fiscal 2026. Eagle Labs has operated for more than 30 years, serving North Texas and surrounding areas with water treatment products and technical services.

Metric	Before the deal	After the deal
Hawkins Texas Water Treatment sites	5	7
Eagle Labs tenure	30+ years	Absorbed into Hawkins

Hawkins' headquarters remain in Roseville, Minnesota. The company did not disclose the purchase price, the acquired revenue, EBITDA contribution, or the number of Eagle Labs employees joining the organization. It also did not state whether the transaction is expected to be accretive in any specific fiscal year.

For a peer comparison, the report offers none. It names no competitor, no sector index, and no valuation multiple. Hawkins describes itself as a leading water treatment and specialty ingredients company that formulates, manufactures, distributes and blends products across three segments: Water Treatment, Food & Health Sciences, and Industrial Solutions.

The two relevant dates in the report are fiscal 2022, when Hawkins entered Texas, and the 29 September 2026 closing. Fiscal 2026 revenue of about $1.1 billion and a headcount of about 1,200 are the only financial-scale figures provided, and both are company-wide rather than Texas-specific.

Analysis — what it means for markets, sectors and tickers

The deal is small in dollar terms but tells you where Hawkins expects to spend. Water treatment demand tracks municipal and industrial water infrastructure, which is a slow, regulated, contract-driven market rather than a cyclical one. Adding two DFW sites plus a new company facility concentrates Hawkins' Texas exposure in the state's fastest-growing metro, where population growth pulls municipal water systems and industrial users into the same service radius.

The customer-service model and coagulant and polymer expertise Hawkins cites are the parts of Eagle Labs that are hardest to replicate organically. Coagulants and polymers are consumable chemistry sold on technical service and reliability, so an installed customer base with local relationships is the asset Hawkins is buying. Hodel said Hawkins shares his company's values and commitment to serving customers — a seller's endorsement, not an operating guarantee.

The limitation is disclosure. Without a purchase price, acquired revenue, or an accretion timeline, a reader cannot size the deal against Hawkins' roughly $1.1 billion revenue base. Hawkins also did not address integration risk, customer retention at Eagle Labs, or whether the new DFW Hawkins facility duplicates any Eagle Labs capability. Those are the questions that determine whether seven Texas sites produce use or overlap.

Positioning is straightforward. Hawkins is a small-cap specialty chemicals and water treatment name held by investors who want steady infrastructure-linked cash flows, and this transaction reads as a bolt-on funded from the balance sheet rather than a transformational bet. The announced completion removes deal risk from the story; the undisclosed price leaves valuation work to the next quarterly filing.

Outlook — what to watch next

The next hard datapoint is Hawkins' fiscal third-quarter earnings report, when the company would typically discuss acquisition contributions and segment performance. The report gives no earnings date, so the timing is unknown.

Watch for any disclosure of purchase price or acquired revenue in Hawkins' subsequent filings, and for whether the company restates its Texas site count or segment structure to reflect the two added locations and the new DFW facility. Any commentary on coagulant and polymer volumes in the Water Treatment segment would be the clearest read on whether the Eagle Labs book is tracking as expected.

Second, watch whether Hawkins signals further Texas consolidation. The company describes this as continuing a growth path it began in fiscal 2022, and a follow-on deal in the same state would confirm that pattern rather than treat this as a one-off. Third, watch customer retention at Eagle Labs, which Hodel ties to relationships built over three decades; Hawkins said it intends to maintain and expand those connections, and any attrition would surface in Water Treatment volumes.

Frequently Asked Questions

What does the Hawkins and Eagle Labs deal mean for retail investors?

For most retail investors the transaction matters as a signal about Hawkins' capital allocation rather than as a standalone financial event. Hawkins said the purchase extends its Dallas–Fort Worth reach and takes its Texas Water Treatment count to seven sites. The company did not disclose the purchase price, acquired revenue, or an accretion estimate, so the deal cannot be sized against Hawkins' roughly $1.1 billion of fiscal 2026 revenue from the announcement alone.

Why did Eagle Labs agree to sell to Hawkins?

Founder and CEO Dwight Hodel framed the sale as succession, saying it was time to find one company to trust with the legacy built by his employees, customers and suppliers over more than 30 years. He cited shared values and Hawkins' resources and dedication to excellence. The report does not disclose whether Hodel retains any role, whether any Eagle Labs employees are staying, or what consideration changed hands.

What happens next for Hawkins' Texas operations?

Hawkins says it will keep and expand Eagle Labs' local community relationships while folding the coagulant and polymer offering into its statewide Water Treatment business. The company has also opened a new Hawkins facility in the Dallas–Fort Worth area alongside the two acquired sites. There is no disclosed integration timeline, so the first formal update would come with Hawkins' next quarterly results or filing.

Bottom Line

Hawkins has converted a 30-year North Texas distributor into two more sites in its fastest-growing state market, but the undisclosed price leaves the deal unsized.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.